OK We use cookies to enhance your visit to our site and to bring you advertisements that might interest you. Read our Privacy and Cookies policies to find out more.
OK We use cookies to enhance your visit to our site and to bring you advertisements that might interest you. Read our Privacy and Cookies policies to find out more.
Back to Overview

The Problem of Ascites

Ascites is a common complication among patients with late-stage liver disease and is the leading reason for hospitalization among patients with cirrhosis. Paracentesis, which involves inserting a large-bore needle into the abdomen to drain 5-10 litres of accumulated ascites, is the most common procedure for the treatment of refractory ascites. However, paracentesis has to be repeated frequently, often every 7-10 days, as it doesn’t prevent the re-accumulation of fluid. This repeated procedure is burdensome both to the patient and healthcare service provider.

The ALFApump® System

The ALFApump System® provides refractory ascites patients with a completely new treatment option. It is a fully implantable system, which collects ascites as it forms and moves it into the bladder, where it is eliminated from the patient through normal urination. The implantation procedure is minimally invasive and takes around one hour. Once implanted, patient interaction with the device is minimal. The patient simply charges the ALFApump wirelessly through the skin by holding a hand-held charging device over the pump. While charging, history of all pump activity is transferred to this charger. This data can be accessed by the physician during follow-up visits and settings can be changed as appropriate.

The ALFApump System significantly reduces the need for large-volume paracentesis. Patients no longer experience the discomfort of chronic ascites accumulation and the number of hospital visits for paracentesis drops significantly, improving patient quality of life.

About Sequana Medical

Sequana Medical AG is a Swiss medical device company dedicated to improving patient lives through innovative technologies to manage fluid overload in patients suffering from liver disease, cancer and congestive heart failure.